4//SEC Filing
ROMANO KATHRYN 4
Accession 0001801385-24-000009
CIK 0001711279other
Filed
Feb 29, 7:00 PM ET
Accepted
Mar 1, 8:16 PM ET
Size
56.6 KB
Accession
0001801385-24-000009
Insider Transaction Report
Form 4
ROMANO KATHRYN
Chief Accounting Officer
Transactions
- Sale
Common Stock
2024-02-28$163.49/sh−786$128,506→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+1,600$101,680→ 14,536 total - Sale
Common Stock
2024-02-28$164.84/sh−1,600$263,751→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+200$12,710→ 13,136 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+523$33,237→ 13,459 total - Sale
Common Stock
2024-02-28$163.13/sh−523$85,319→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+744$47,281→ 13,680 total - Sale
Common Stock
2024-02-28$164.60/sh−744$122,465→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+130$8,262→ 13,066 total - Sale
Common Stock
2024-02-28$165.22/sh−130$21,479→ 12,936 total - Sale
Common Stock
2024-02-28$162.73/sh−637$103,656→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+786$49,950→ 13,722 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+100$6,355→ 13,036 total - Sale
Common Stock
2024-02-28$166.22/sh−100$16,622→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+700$44,485→ 13,636 total - Sale
Common Stock
2024-02-28$169.09/sh−1,133$191,585→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+134$8,516→ 13,070 total - Sale
Common Stock
2024-02-28$171.66/sh−134$23,002→ 12,936 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-28−2,500→ 35,000 totalExercise: $63.55Exp: 2032-02-28→ Common Stock (2,500 underlying) - Sale
Common Stock
2024-02-28$169.47/sh−203$34,402→ 12,936 total - Sale
Common Stock
2024-02-28$171.45/sh−100$17,145→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+637$40,481→ 13,573 total - Sale
Common Stock
2024-02-28$167.85/sh−300$50,355→ 12,936 total - Sale
Common Stock
2024-02-28$169.75/sh−210$35,648→ 12,936 total - Sale
Common Stock
2024-02-28$168.91/sh−700$118,240→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+203$12,901→ 13,139 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+100$6,355→ 13,036 total - Sale
Common Stock
2024-02-28$166.04/sh−200$33,208→ 12,936 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+300$19,065→ 13,236 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+1,133$72,002→ 14,069 total - Exercise/Conversion
Common Stock
2024-02-28$63.55/sh+210$13,346→ 13,146 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-28−5,000→ 30,000 totalExercise: $63.55Exp: 2032-02-28→ Common Stock (5,000 underlying)
Footnotes (16)
- [F1]The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share.
- [F10]The transaction was executed in multiple trades ranging from $164.360 to $165.270. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F11]The transaction was executed in multiple trades ranging from $165.980 to $166.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F12]The transaction was executed in multiple trades ranging from $167.540 to $168.010. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F13]The transaction was executed in multiple trades ranging from $168.680 to $169.500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F14]The transaction was executed in multiple trades ranging from $169.690 to $169.970. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F15]The transaction was executed in multiple trades ranging from $171.460 to $172.230. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F16]50,000 options were granted that vest in four equal annual installments with the first installment vesting on February 28, 2023.
- [F2]The transaction was executed in multiple trades ranging from $162.825 to $163.820. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The transaction was executed in multiple trades ranging from $164.030 to $164.960. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The transaction was executed in multiple trades ranging from $165.050 to $165.270. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]The transaction was executed in multiple trades ranging from $168.275 to $169.190. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F6]The transaction was executed in multiple trades ranging from $169.345 to $170.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F7]The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share.
- [F8]The transaction was executed in multiple trades ranging from $162.115 to $163.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F9]The transaction was executed in multiple trades ranging from $163.120 to $164.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Documents
Issuer
Krystal Biotech, Inc.
CIK 0001711279
Entity typeother
Related Parties
1- filerCIK 0001801385
Filing Metadata
- Form type
- 4
- Filed
- Feb 29, 7:00 PM ET
- Accepted
- Mar 1, 8:16 PM ET
- Size
- 56.6 KB